Isomorphic Labs CEO Demis Hassabis with Endpoints' Andrew Dunn at the Financial Times' Global Pharma and Biotech Summit (courtesy Financial Times)
November 7, 2024 09:00 AM ESTUpdated 12:32 PM
People
AI

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

Andrew Dunn

Senior Biopharma Correspondent

LON­DON — Demis Has­s­abis is pur­su­ing one of the bold­est ef­forts of bring­ing AI in­to biotech, build­ing out the Al­pha­bet-backed start­up Iso­mor­phic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times